MYCN and neuroblastoma: High-level CD9 expression in neuroblastomas from the 476-tumor cohort also significantly correlated with established clinical and molecular markers for favorable tumor biology, including INSS localized or 4S disease stages, age at diagnosis ≤ 18 months, favorable Shimada/International Neuroblastoma Pathology Classification (INPC) tumor histology, lack of MYCN amplifications or 1p aberrations and a low-risk tumor transcriptional profile previously defined by PAM analysis [23] (Figure 2G-2L).